IFFIm Board meets in Geneva, plans role in global pandemic preparedness
IFFIm Board meets in Geneva, plans role in global pandemic preparedness
14 July 2022
Seth Berkley, José Manuel-Barroso and Ken Lay. Credit: Carol Piot.
IFFIm’s Board of Directors convened at Gavi headquarters in Geneva the week of 20 June.
IFFIm’s Board of Directors convened at Gavi headquarters in Geneva the week of 20 June. Over five days of meetings and events, they charted future priorities, acknowledging the realities confronting Gavi’s work in an uncertain world, and confirmed their strong interest in IFFIm playing a role in the future global health architecture for pandemic preparedness and response. The board was pleased to have Gavi Vice-Chair Sarah Goulding attend their meeting as an observer.
Discussing IFFIm’s impact on global health, Gavi CEO Dr Seth Berkley said that throughout 2020 and 2021, Gavi was able to leverage IFFIm’s capability to provide timely funding at scale, disbursing more than US$ 800 million in IFFIm funds for immunisation programmes and US$ 211 in funding for COVAX in those two years alone. (Gavi has disbursed more than US$ 4.1 million in IFFIm funding for immunisation programmes since IFFIm’s inception in 2006.)
He added that IFFIm will remain a key resource for Gavi over the 2023-2025 period with IFFIm support expected to be close to US$ 3.3 billion for core programmes, as well as additional frontloading proceeds for the COVAX AMC.
Dr Berkley also congratulated Doris Herrera-Pol and Helge Weiner-Trapness on their reappointments as members of the IFFIm Board of Directors and expressed his appreciation for their continuing commitment to Gavi’s mission.
While in Geneva, IFFIm board members participated in Gavi’s board meeting as observers, with IFFIm Board Chair Ken Lay presenting an update on IFFIm.
Doris Herrera-Pol, Ken Lay and Ingrid van Wees. Credit: Gainha Kim.
The Gavi Board announced several decisions, including driving a renewed focus on vaccine equity, providing greater support for fragile and conflict countries and integrating COVAX into core routine immunisation services.
In the face of conflicts and humanitarian crises, the Gavi Board also approved a revision to their fragility, emergencies and displaced populations policy because, said Dr Berkley, “ensuring access for all displaced communities is the true test of our resolve for vaccine equity.”
Speaking about the outcomes of the June gathering, Gavi Board Chair José Manuel Barroso added, "Gavi’s Board has provided unequivocal backing to the organisation as it strives to restore and maintain routine immunisation, reach zero dose children and help bring the current and future pandemics under control."
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.
IFFIm welcomes Augustin Flory
24 April 2024